China biotech remains a market bright spot with strong growth, driven by out-licensing, efficiency improvements and cost control
China’s healthcare sector is on track to secure record fundraising this year, driven by robust global investor demand and growth momentum, according to analysts.
Several Chinese biopharmaceutical companies have tapped equity capital markets – mainly in Hong Kong – for initial public offerings (IPOs), follow-on deals and block share placements this year.
Year to date, the fundraising reached US$10.6 billion (HK$82.5 billion), more than the combined total from 2022 to 2024, according to Dealogic data.
Your personal data will be processed and information from your device (cookies, unique identifiers, and other device data) may be stored by, accessed by and shared with 89 TCF vendor(s) and 20 ad partner(s), or used specifically by this site or app.
